Navigation Links
New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation
Date:4/19/2012

COCOA, Fla., April 19, 2012 /PRNewswire/ -- New data presented today studied the safety of the GeNO  system for delivering inhaled nitric oxide (NO) to patients being evaluated for cardiac transplant.  GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, announced that a study of GeNO's NITROSYL Delivery System during Right Heart Catheterization (RHC) in subjects being evaluated for Orthotopic Heart Transplantation (OHT) and Left Ventricular Assist Device (LVAD) implantation was presented at the International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting in Prague, Czech Republic.

The study was led by Dr. Andrew Boyle, Medical Director of Heart Failure, Cardiac Transplantation and Mechanical Circulatory Support at Aurora St. Luke's Medical Center in Milwaukee, and evaluated 10 heart failure patients who underwent RHC prior to cardiac transplant or LVAD implant.  

GeNO's NITROSYL Delivery System was used to deliver NO at a concentration of 80 PPM for 15 minutes by nasal cannula with air or O2. Results showed that in eight patients who received NO in air, the levels of nitrogen dioxide (NO2) in the gas that was delivered varied from 0.04 PPM to 0.06 PPM. Two patients received NO in O2 with NO2 levels in the gas varying from 0.25 to 0.35 PPM. Device performance was evaluated by measuring the amount of NO2 delivered to the patients as monitored by cavity attenuated phase-shift spectroscopy (CAPS) which can accurately detect NO2 down to 0.006 PPM. Cardiac hemodynamics were measured prior to and following 15 minutes of NO exposure.  Clinically meaningful hemodynamic changes were not seen after such a short exposure to NO including PAP, PCWP, CO, CI, and PVR.

"The GeNO device reproducibly provided NO with low levels of NO2 in air or O2.  The NO2 levels were considerably below the FDA limit of 3 PPM and OSHA limit of 5 PPM even in the presence of  oxygen which is known to convert NO to NO2 rapidly," said lead author Dr. Boyle.  "These promising preliminary safety findings, combined with an improved ease of delivery compared with commercially available devices, justify a larger efficacy trial with longer exposure to the device in patients with pulmonary hypertension."

The primary aim of the study was to evaluate the safety, tolerability and device performance of the GeNO NITROSYL Delivery System during RHC. Secondary considerations were to confirm that inhaled NO generated by the system reduces pulmonary vascular resistance (PVR) in patients with reversible pulmonary hypertension and contains levels of NO2 well below the upper level of acceptable exposure. The study title is "An Open Label Non-Randomized Pilot Study To Evaluate the Safety of the GeNO NITROSYL Delivery System in Patients Being Evaluated for Heart Transplantation."

This is the first human data to be presented with the Company's novel NO delivery system that converts nitrogen dioxide in either balance air or oxygen to nitric oxide. The gas is allowed to flow through a proprietary cartridge containing ascorbic acid, which generates nitric oxide immediately prior to inhalation.  A second cartridge is provided for redundancy.

"We are pleased to see these study results, as the purity of nitric oxide produced by our unique technology will be of interest to many health care professionals who use NO to treat a variety of life threatening conditions and diseases," said GeNO LLC Founder and President David Fine. "We remain committed to moving both our in-hospital solution and our ambulatory system through clinical development."

GeNO's NITROSYL Delivery System could add valuable options for clinicians treating a range of serious pulmonary and cardiac diseases with inhaled nitric oxide. GeNO's plans for both in-hospital and ambulatory inhaled nitric oxide systems will help address the cost, complexity and lack of portability of current treatment regimens, and potentially reach a much larger group of patients. At present, GeNO's delivery technologies are investigational and are not approved by regulatory authorities.

GeNO recently completed a 10 patient Phase 2 pilot study of NITROSYL as a diagnostic in Pulmonary Arterial Hypertension (PAH) to obtain preliminary safety and feasibility data and is currently performing a dose-escalation trial for the treatment of Pulmonary Hypertension in patients with PAH and Pulmonary Hypertension secondary to Idiopathic Pulmonary Fibrosis (PH-IPF). Additional study details can be found on http://clinicaltrials.gov/ -- ClinicalTrials.gov Identifier NCT01265888. 

ABOUT GENO LLC                                        
GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the true potential of inhaled nitric oxide to be realized. The company is focused on applying the new technology to deliver inhaled nitric oxide to patients in a wide variety of settings, including ambulatory and in-home use for potential chronic treatment. GeNO's NITROSYL Systems will be regulated by the FDA as new drugs with their own NDAs. These systems have been designated as Combination Products by the FDA Office of Combination Products, with the Division of Cardiovascular and Renal Products designated as the lead reviewer for GeNO's initial INDs.

ABOUT AURORA HEALTH CARE
Aurora Health Care is a not-for-profit Wisconsin based health care provider and a national leader in efforts to improve the quality of care. Aurora provides care at sites in more than 90 communities throughout eastern Wisconsin and northern Illinois.

Media Contacts:


Carla Burigatto, 610-457-2178   

Brian Heffron, 781-799-9568

cburigatto@gmail.com

bheffron@ctpboston.com


'/>"/>
SOURCE GeNO LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
2. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
3. Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures
4. Oil palm plantations are no substitute for tropical rainforests, a new study shows
5. New carbon material shows promise of storing large quantities of renewable electrical energy
6. Research Shows How AHCC(R) May Help Fight Flu and Other Infectious Agents
7. Jellyfish Protein Shows Potential to Help With Memory
8. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
9. New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
10. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
11. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
Breaking Biology Technology:
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
Breaking Biology News(10 mins):